Codruta Chiuzan

Codruta Chiuzan

Codruta Chiuzan

Assistant Professor
Biostatistics at the Columbia University Medical Center


722 West 168th Street, Room 646
New York NY 10032
(212) 305-9107


Dr. Chiuzan's statistical research area focuses on development of early phase clinical trial designs, with particular interest in cancer targeted and immunotherapeutic agents. She currently serves as one of the main statisticians for the Herbert Irving Comprehensive Cancer Center and as Director for the Biostatistics Fee-For-Service Consulting Program. Recently, she has been named as the Director for Educational Initiatives of CTSA Biostatistics, Epidemiology and Research Design Resource (BERD) Resource.



PhD, 2014, Medical University of South Carolina
MS, 2009, University of South Carolina

Columbia Affiliations

Biostatistician, Irving Cancer Center

Other Affiliations

Member, Society for Clinical Trials
Member, American Association for Cancer Research

Honors & Awards

Calderone Junior Faculty Research Award, 2015

Areas of Expertise

Clinical Trials, Longitudinal Studies, Multilevel Modeling, Research Design and Methods, Survival Analysis, Cancer

Select Publications

Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Chiuzan C, Khan K, Atkins L, Rada A, Kim HA, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 2018;131(4):397-407, PMID: 29141948.
Chiuzan C, Elizabeth Garrett-Mayer & Michael Nishimura (2018) An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials, Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2018.1462727
NA Wages, C Chiuzan, KS Panageas. Design considerations for early-phase clinical trials of immune-oncology agents, Journal for immunotherapy of cancer, 2018,
Chiuzan, C., Shtaynberger, J., Manji, G. A., Duong, J. K., Schwartz, G. K., Ivanova, A., & Lee, S. M. (2017). Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Journal of Biopharmaceutical Statistics, 27(3), 477-494. DOI: 10.1080/10543406.2017.1289952
Chiuzan C, Garrett-Mayer E, Yeatts SD. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clin Trials. 2015 Feb;12(1):24-33. doi: 10.1177/1740774514555585.
Muennig PA, Quan R, Chiuzan C, Glied S. Considering whether Medicaid is worth the cost: revisiting the Oregon Health Study. Am J Public Health. 2015 May;105(5):866-71. doi: 10.2105/AJPH.2014.302485. Epub 2015 Mar 19.
Kiran RP, Murray AC, Chiuzan C, Estrada D, Forde K. Combined Preoperative Mechanical Bowel Preparation With Oral Antibiotics Significantly Reduces Surgical Site Infection, Anastomotic Leak, and Ileus After Colorectal Surgery. Ann Surg. 2015 Sep;262(3):416-25. doi: 10.1097/SLA.0000000000001416.
Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med. 2015 Jan;4(1):1-6. doi: 10.1002/cam4.315. Epub 2014 Aug 28.
Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK. Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res. 2012 Mar;36(3):490-6. doi: 10.1111/j.1530-0277.2011.01645.x. Epub 2011 Sep 20.

See a complete list of publicationsBack to Top